Skip to main content

Advertisement

SpringerLink
Log in

Bevacizumab bei therapierefraktärer Epistaxis

Fallbericht einer niedrigdosierten, submukös injizierten Antikörpertherapie bei M. Osler

Bevacizumab in therapy-refractory epistaxis

Case report of low-dose antibody therapy for hereditary hemorrhagic telangiectasia

  • Kasuistiken
  • Published:
HNO Aims and scope Submit manuscript

Zusammenfassung

Wir berichten über die submuköse Injektion von Bevacizumab (Avastin) in einer Dosierung von 0,3–3,75 mg pro Seite bei einer Patientin mit M. Osler. In der Literatur ist die Anwendung einer solch niedrigen Menge bis jetzt noch nicht beschrieben. In dem dargestelltem Fallbericht zeigte sich eine positive Wirkung auf die mit anderen nichtinvasiven Therapien kaum beherrschbare Epistaxis. Nebenwirkungen traten nicht auf.

Abstract

We report on the submucosal injection of bevacizumab (Avastin) at a dose of 0.3 to 3.75 mg per side in a patient with hereditary hemorrhagic telangiectasia. Application of such low doses has not been described in the literature yet. Our case report shows the positive effect of low-dose bevacizumab on therapy-refractory epistaxis. No complications were caused by the bevacizumab treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Chen S, Karnezis T, Davidson TM (2011) Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 121:644–646

    Article  PubMed  CAS  Google Scholar 

  2. Cirulli A, Liso A, D’Ovidio F et al (2003) Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol 110:29–32

    Article  PubMed  CAS  Google Scholar 

  3. Flieger D, Hainke S, Fischbach W (2006) Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 85:631–632

    Article  PubMed  Google Scholar 

  4. Folz B, Wollstein AC, Lippert BM et al (2005) Morphology and distribution of nasal telangiectasia in HHT-patients with epistaxis. Am J Rhinol 19(1):65–70

    PubMed  Google Scholar 

  5. Geisthoff UW, Schneider G, Fischinger J et al (2002) Hereditäre hämorrhagische Teleangiektasie (Morbus Osler). HNO 50:114–128

    Article  PubMed  CAS  Google Scholar 

  6. Karnezis TT, Davidson TM (2011) Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. Laryngoscope 121:636–638

    Article  PubMed  CAS  Google Scholar 

  7. Kuehnel TS, Wagner BH, Schurr CP et al (2005) Clinical strategy in hereditary hemorrhagic telangiectasia. Am J Rhinol 19:508–513

    Google Scholar 

  8. McDonald JE, Miller FJ, Hallam SE et al (2000) Clinical manifestations in a large hereditary hemorrhagic telangiectasia (HHT) type 2 kindred. Am J Med Genet 93:320–327

    Article  PubMed  CAS  Google Scholar 

  9. Meyer CH, Helb HM, Eter N (2008) Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series. Ophthalmologe 105:125–132

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik für Hals-Nasen-Ohren-Heilkunde, Kopf- und Halschirurgie, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Deutschland

    C. Rohrmeier & T.S. Kühnel

Authors
  1. C. Rohrmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T.S. Kühnel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Rohrmeier.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rohrmeier, C., Kühnel, T. Bevacizumab bei therapierefraktärer Epistaxis. HNO 60, 1003–1006 (2012). https://doi.org/10.1007/s00106-011-2458-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00106-011-2458-x

Schlüsselwörter

Keywords

Search

Navigation